Nicholas E Tan1, Shannon X Chen1, Nathan M Radcliffe2,3. 1. College of Medicine, State University of New York Downstate Health Sciences University, Brooklyn, NY, USA. 2. Department of Ophthalmology, Mount Sinai School of Medicine, New York, NY, USA. drradcliffe@gmail.com. 3. New York Eye Surgery Center, Bronx, NY, USA. drradcliffe@gmail.com.
Abstract
PURPOSE: To determine factors associated with vision loss 1 year after Ahmed glaucoma valve (AGV) surgery in Black or Hispanic patients, who bear disproportionate glaucoma burdens yet have been underrepresented in pivotal trials. METHODS: This retrospective study included Black or Hispanic patients who received AGVs standalone or combined with phacoemulsification and/or cyclodestructive lasers. Univariate and multivariate generalized estimating equations evaluated the effects of baseline, surgical, and postoperative factors on vision loss of two Snellen lines or more at the 1-year follow-up visit. The primary term was the hypertensive phase (HP), which signified an intraocular pressure (IOP) reading > 21 mmHg within the first 3 postoperative months after reduction below 22 in the first week, without other tube malfunction. RESULTS: Of 241 eyes from 186 patients, vision loss of ≥ 2 lines at the 1-year follow-up visit occurred in 21.6% (N = 52). Vision loss of ≥ 2 lines occurred in 52.5% of eyes at week 1, 36.9% of eyes at month 1, and 27.0% of eyes at month 3. Between 6 months and 1 year, vision loss frequencies stabilized. In the multivariate model, HP (OR = 4.71 (2.14, 10.38)), total quadrants with split fixation (1.47 (1.20, 1.81)), follow-up non-glaucomatous eye pathology (2.89 (1.44, 5.80)), and concurrent cataract surgery (0.42 (0.22, 0.82)) each met significance (p < 0.05). CONCLUSION: Post-AGV vision loss in the early follow-up period among Black or Hispanic patients was often transient. Hypertensive phase and split fixation each increased the odds of vision loss at 1 year, while concurrent cataract surgery decreased the odds.
PURPOSE: To determine factors associated with vision loss 1 year after Ahmed glaucoma valve (AGV) surgery in Black or Hispanic patients, who bear disproportionate glaucoma burdens yet have been underrepresented in pivotal trials. METHODS: This retrospective study included Black or Hispanic patients who received AGVs standalone or combined with phacoemulsification and/or cyclodestructive lasers. Univariate and multivariate generalized estimating equations evaluated the effects of baseline, surgical, and postoperative factors on vision loss of two Snellen lines or more at the 1-year follow-up visit. The primary term was the hypertensive phase (HP), which signified an intraocular pressure (IOP) reading > 21 mmHg within the first 3 postoperative months after reduction below 22 in the first week, without other tube malfunction. RESULTS: Of 241 eyes from 186 patients, vision loss of ≥ 2 lines at the 1-year follow-up visit occurred in 21.6% (N = 52). Vision loss of ≥ 2 lines occurred in 52.5% of eyes at week 1, 36.9% of eyes at month 1, and 27.0% of eyes at month 3. Between 6 months and 1 year, vision loss frequencies stabilized. In the multivariate model, HP (OR = 4.71 (2.14, 10.38)), total quadrants with split fixation (1.47 (1.20, 1.81)), follow-up non-glaucomatous eye pathology (2.89 (1.44, 5.80)), and concurrent cataract surgery (0.42 (0.22, 0.82)) each met significance (p < 0.05). CONCLUSION: Post-AGV vision loss in the early follow-up period among Black or Hispanic patients was often transient. Hypertensive phase and split fixation each increased the odds of vision loss at 1 year, while concurrent cataract surgery decreased the odds.
Authors: Panos G Christakis; Jeffrey W Kalenak; David Zurakowski; James C Tsai; Jeffrey A Kammer; Paul J Harasymowycz; Iqbal I K Ahmed Journal: Ophthalmology Date: 2011-09-01 Impact factor: 12.079
Authors: Panos G Christakis; Dongyu Zhang; Donald L Budenz; Keith Barton; James C Tsai; Iqbal I K Ahmed Journal: Am J Ophthalmol Date: 2017-01-17 Impact factor: 5.258
Authors: Donald L Budenz; Keith Barton; William J Feuer; Joyce Schiffman; Vital P Costa; David G Godfrey; Yvonne M Buys Journal: Ophthalmology Date: 2010-10-08 Impact factor: 12.079
Authors: Steven J Gedde; Joyce C Schiffman; William J Feuer; Leon W Herndon; James D Brandt; Donald L Budenz Journal: Am J Ophthalmol Date: 2006-09-01 Impact factor: 5.258
Authors: Steven J Gedde; Kateki Vinod; Martha M Wright; Kelly W Muir; John T Lind; Philip P Chen; Tianjing Li; Steven L Mansberger Journal: Ophthalmology Date: 2020-11-12 Impact factor: 14.277
Authors: Steven J Gedde; William J Feuer; Wei Shi; Kin Sheng Lim; Keith Barton; Saurabh Goyal; Iqbal I K Ahmed; James Brandt Journal: Ophthalmology Date: 2018-02-21 Impact factor: 12.079
Authors: Esther Lee Kim; Jeffrey Tran; Marc Töteberg-Harms; Jasdeep Chahal; Douglas Rhee; Vikas Chopra; Brian Francis Journal: J Ophthalmol Date: 2017-01-18 Impact factor: 1.909